Alkem Laboratories Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Alkem Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 13.6% bzw. 9.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.3% betragen.
Wichtige Informationen
11.3%
Wachstumsrate der Gewinne
11.1%
EPS-Wachstumsrate
Pharmaceuticals Gewinnwachstum | 18.0% |
Wachstumsrate der Einnahmen | 9.8% |
Zukünftige Eigenkapitalrendite | 19.0% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 13 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Recent updates
What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 03Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Feb 08Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?
Jan 09Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Nov 30Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
3/31/2027 | 166,658 | 27,689 | 20,412 | N/A | 13 |
3/31/2026 | 152,243 | 25,533 | 16,794 | N/A | 21 |
3/31/2025 | 137,893 | 22,166 | 13,804 | N/A | 21 |
6/30/2024 | 127,317 | 20,542 | N/A | N/A | N/A |
3/31/2024 | 126,676 | 17,958 | 16,888 | 19,481 | N/A |
12/31/2023 | 126,344 | 15,732 | N/A | N/A | N/A |
9/30/2023 | 123,514 | 14,329 | 18,370 | 20,537 | N/A |
6/30/2023 | 119,906 | 11,433 | N/A | N/A | N/A |
3/31/2023 | 115,993 | 9,842 | 14,496 | 16,825 | N/A |
12/31/2022 | 111,805 | 10,208 | N/A | N/A | N/A |
9/30/2022 | 107,586 | 10,917 | 5,527 | 8,426 | N/A |
6/30/2022 | 104,792 | 13,051 | N/A | N/A | N/A |
3/31/2022 | 106,342 | 16,456 | 7,721 | 11,110 | N/A |
12/31/2021 | 103,425 | 17,780 | N/A | N/A | N/A |
9/30/2021 | 100,416 | 17,033 | 10,478 | 13,213 | N/A |
6/30/2021 | 96,044 | 16,311 | N/A | N/A | N/A |
3/31/2021 | 88,650 | 15,850 | 11,051 | 12,649 | N/A |
12/31/2020 | 87,218 | 15,338 | N/A | N/A | N/A |
9/30/2020 | 85,971 | 14,648 | 8,916 | 11,455 | N/A |
6/30/2020 | 84,984 | 13,636 | N/A | N/A | N/A |
3/31/2020 | 83,444 | 11,271 | 2,220 | 5,851 | N/A |
12/31/2019 | 81,484 | 11,057 | N/A | N/A | N/A |
9/30/2019 | 78,929 | 9,262 | 5,173 | 8,756 | N/A |
6/30/2019 | 75,478 | 8,098 | N/A | N/A | N/A |
3/31/2019 | 73,572 | 7,605 | 2,505 | 7,797 | N/A |
12/31/2018 | 70,157 | 6,602 | N/A | N/A | N/A |
9/30/2018 | 68,318 | 6,293 | N/A | N/A | N/A |
6/30/2018 | 67,788 | 6,955 | N/A | N/A | N/A |
3/31/2018 | 63,918 | 6,309 | N/A | 2,660 | N/A |
12/31/2017 | 60,044 | 7,009 | N/A | N/A | N/A |
9/30/2017 | 57,285 | 7,626 | N/A | N/A | N/A |
6/30/2017 | 55,019 | 7,248 | N/A | N/A | N/A |
3/31/2017 | 56,875 | 8,920 | N/A | 4,711 | N/A |
12/31/2016 | 56,933 | 7,732 | N/A | N/A | N/A |
9/30/2016 | 54,992 | 7,267 | N/A | N/A | N/A |
6/30/2016 | 52,419 | 7,108 | N/A | N/A | N/A |
3/31/2016 | 49,248 | 7,416 | N/A | 7,258 | N/A |
12/31/2015 | 47,975 | 8,189 | N/A | N/A | N/A |
9/30/2015 | 44,556 | 7,227 | N/A | 4,023 | N/A |
6/30/2015 | 40,459 | 5,781 | N/A | N/A | N/A |
3/31/2015 | 37,434 | 3,916 | N/A | 3,255 | N/A |
3/31/2014 | 31,191 | 4,353 | N/A | 2,900 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ALKEMDas prognostizierte Gewinnwachstum (13.6% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: ALKEMDie Erträge des Unternehmens (13.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (16% pro Jahr).
Hohe Wachstumserträge: ALKEMDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ALKEMDie Einnahmen des Unternehmens (9.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (9.9% pro Jahr).
Hohe Wachstumseinnahmen: ALKEMDie Einnahmen des Unternehmens (9.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ALKEMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.3%).